- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01735656
Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions
Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting in the Treatment of True Bifurcation Lesions: a Multicenter, Noninferior, Randomized, Controlled Trial (the DK Culotte-I Study)
Study Overview
Detailed Description
How to properly treat coronary bifurcation lesion (BL) is still controversial in the field of percutaneous coronary intervention (PCI). The current guidelines recommended simpler strategies, single crossover stenting or provisional stenting, as the preferred treatment. However, the acute occlusion or loss of important branches, which affects immediate as well as long-term outcomes, may result from such simpler strategies as treating severe true bifurcation lesion (TBL). Therefore, for the procedural safety, double stenting is clinically necessary particularly in treatment of major vessel bifurcation lesions.
Up to date, a great number of double-stenting techniques have been introduced clinically: crush stenting (classic crush, mini-crush, step-crush, DK-crush), culotte stenting (classic or modified culotte stenting), T-stenting (classic or modified T), and V-stenting (step V-stenting, simultaneous kissing stenting). Of which, crush-based and culotte-based stenting have been the most popular techniques.
The DK-crush has been demonstrated as a safe and efficient procedure, which can effectively elevate the success rate of final kissing balloon inflation (FKBI) and reduce long-term major adverse cardiac events (MACE). However, in the clinical real world, especially when the bifurcation angle was relative small or parallel, the DK-crush still has several limitations: (1) although initial kissing balloon inflation (IKBI) can push away the struts covering the side-branch ostium and remold the geometric shape of orifice, redundant struts will be crushed aside onto parent-vessel wall and the side-branch ostium, thereby inducing turbulent flow due to local unsmooth vessel lumen; (2) once the main-vessel stent was released, the side-branch orifice will be squeezed crushed again, thus resulting in stent deformation, malapposition or incomplete coverage near the bifurcation arena and carina; (3) because of deformation or crush of the side-branch stent at its ostium, rewiring the side-branch may be extremely hard with subsequent balloon passing difficulty, leading to low quality or failure of FKBI, or sometimes stent destruction as the wire runs out of the stent.
Culotte-based stenting has been demonstrated superior to crush-based stenting in reduction of the side-branch restenosis though overall MACE is similar in Nordic studies [PMID: 20031690]. However, it is an essential requirement of similar size of the two branches when using the conventional culotte stenting. As firstly described by us, the modified culotte stenting [PMID: 22088451], to start with stenting the side-branch (smaller branch) and by pre-imbedding a balloon in the main-branch for prevention of acute branch loss, has no strict requirement of similar size of the two branches and has been proven to be a safe and efficient procedure for treatment of TBL. However, if the diameter difference between two branches is too much (>0.75 mm), a circular under-expansion band (CUEB) of main-branch stent in the parent vessel near the bifurcation arena will frequently occurred since the side-branch stent implanted earlier will limit the expansion of the main-branch stent implanted subsequently by its side-hole and the portion protruding into the parent vessel, leading to local stent malapposition and the risk of in-stent thrombosis. For overcome CUEB, we further improved culotte-based stenting to order to develop a novel culotte stenting, the DK-mini-culotte stenting, by the following modifications: (1) pre-imbedding a balloon in the main-branch for prevention of acute vessel loss, (2) firstly stenting the smaller side-branch with shorter protrusion (mini-protrusion) of the stent into the parent vessel, (3) performing IKBI prior to the main-branch stenting for fully expanding the side-hole and protruded portion of the side-branch stent, (4) finally stenting main-branch after IKBI, followed by FKBI.
Our series studies, including mimic stenting in artificial vessel in vitro, hemodynamics and flow-field investigations in vitro or in vivo, and pilot clinical observation, have demonstrated that the DK-mini-culotte stenting is necessary for the achievement of high-quality hemodynamic and morphological results, and is superior to the crush-based techniques for treating TBL.
Particularly, our initial clinical experience has shown the DK-mini-culotte stenting has several advantages: (1) efficiently eliminating CUEB and preventing stent malapposition by IKBI;(2) technically easier to be performed, particularly for wiring/rewiring and for balloon passing during IKBI and FKBI; (3) technically safer to complete the procedure, especially for preventing the acute vessel occlusion or loss; (4) effectively preventing the deformation and collapse that occasionally happened when using the crush-based stenting; (5) mostly close to the general technique for treating BL regardless of size difference of branches and bifurcation angle; (6) potentially long-term benefits because of complete and even stent coverage in the treated segments particularly in the bifurcation arena and carina. However, there remains no strictly compared study to validate whether the above-mentioned technical superiorities can be translated into clinical benefits as using the DK-mini-culotte stenting for treatment of BL.
So, we hypothesized that the DK-mini-culotte stenting is not only feasible technically but also may be superior to or at least not inferior to the DK-crush stenting in terms of reducing in-stent restenosis and MACE. Hereby, we now carry out a head-to-head, prospective, multicentre, non-inferior, randomized and controlled study to compare DK-culotte stenting versus DK-crush stenting in the treatment of TBL.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Beijing Anzhen Hospital
-
Beijing, Beijing, China, 100024
- Peking University first hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Department of Cardiology, Union Hospital, Fujian Medical University
-
Quanzhou, Fujian, China, 362002
- Quanzhou First Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210006
- Nanjing First Hospital
-
Nanjing, Jiangsu, China, 210009
- Southeast University Zhongda Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital
-
Shanghai, Shanghai, China, 200030
- Shanghai Chest Hospital
-
Shanghai, Shanghai, China, 200127
- Renji Hospital Shanghai Jiaotong University
-
Shanghai, Shanghai, China
- East Hospital of Tongji University
-
Shanghai, Shanghai, China
- Xinhua Hospital Affiliated of Shanghai Jiao Tong University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with age of ≥18 and ≤80 years old.
- Patients with stable or unstable angina, or NSTEMI.
- De novo true bifurcation lesions (Medina 0,1,1/1,1,1/1,0,1); MV diameter ≥2.5mm and SB diameter ≥2.25.
- Lesions suitable for PCI (the SYNTAX score <32 if lesions located at LM bifurcation).
- Patients willing to receive all protocol-required evaluations.
- Patients completely understand the trial requirements and treatment procedures and provide written informed consent before any trial-specific tests or procedures are performed.
Exclusion Criteria:
- Patients with STEMI (within 24-hour from the onset of chest pain to admission).
- Lesions not suitable for PCI (the SYNTAX score ≥32 if lesions located at LM bifurcation, or any PCI-related contraindications including patient conditions and/or lesion characteristics).
- A Chronic total occlusion lesion involved in bifurcation
- Lesion with severe calcification that required for rotational atherectomy.
- Patients intolerable to long-term dual anti-platelet therapy.
- Patients with obvious hematopoietic disorders (e.g., platelet count< 100×10^9/L or >700×10^9/L, leukocyte count<3×10^9/L).
- Patients with active bleeding and obviously hemorrhagic tendency (e.g., active ulcer, recent ischemic stroke, previous hemorrhagic stroke, intracranial malignant tumors, recent craniocerebral trauma, or any other active bleeding or hemorrhagic tendency with difficult hemostasis
- Patients with serious renal insufficiency (Scr<30ml/min) or hepatic insufficiency (ALT≧3 times of normal upper limit), heart failure (NYHA class >III class).
- Patients with any other serious medical illness that life expectancy is less than 12 months.
- Woman with pregnancy or planning to pregnancy
- Patients with known allergy to the study stent system (sirolimus, everolimus, zotarolimus) or to protocol-required concomitant medications
- Patients with a planned or planning procedure that may cause non-compliance with the present protocol or confound data interpretation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DK-culotte & Resolute stents
Double kissing culotte technique for true bifurcation lesion with Resolute stents
|
zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
Other Names:
|
Active Comparator: DK-crush & Resolute stents
Double kissing crush technique for true bifurcation lesion with Resolute stents
|
zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of target-lesion failure
Time Frame: 12 months
|
Rate of target-lesion failure, including cardiac death, target-vessel myocardial infarction (MI), and target lesion revascularization (TLR) at 12 months after the procedure.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of target-lesion failure at 30 days,6 months and 24 months after the procedure.
Time Frame: Up to 2 years
|
Rate of target-lesion failure, including cardiac death, target-vessel MI, and target lesion revascularization (TLR) at 30 days,6 months and 24 months after the procedure.
|
Up to 2 years
|
Rate of major adverse cardiac event(MACE)at 30 days,6 months,12 months and 24 months after the procedure.
Time Frame: Immidiately to 24 months after procedure
|
Major adverse cardiac event, including all caused death, all MI, or any vessel revascularization at 30 days,6 months,12 months and 24 after the procedure.
|
Immidiately to 24 months after procedure
|
Number of participants with in-stent thrombosis
Time Frame: Up to 2 years
|
Up to 2 years
|
|
NYHA functional class
Time Frame: Immidiately to 24 months after procedure
|
Immidiately to 24 months after procedure
|
|
Angina CCS classification
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Late lumen loss,in-stent and in-segment restenosis
Time Frame: 12 months
|
Late lumen loss,in-stent and in-segment restenosis which defined as angiographical primary outcome measure, in main vessel (MV) and side branch (SB) identified by angiography at 12th month after PCI
|
12 months
|
Elevation of myocardial markers (CK-MB, cTnT or cTnI) associated with the procedure baseline and 6, 12, or 12 hours after procedure
Time Frame: Baseline and 6, 12, or 12 hours after procedure
|
Elevation of myocardial markers (CK-MB, cTnT or cTnI) associated with the procedure baseline and 6, 12, or 12 hours after procedure
|
Baseline and 6, 12, or 12 hours after procedure
|
Braunwald classification
Time Frame: Up to 2 years
|
Up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who experienced stroke
Time Frame: up to 2 years
|
up to 2 years
|
|
Contrast volume used procedurally
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
|
Procedural time
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
|
Procedural X-ray exposure time
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
|
Procedural X-ray dosage
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
|
All-procedure, angiographic, and fluoroscopic dosage-area product (DAP)
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
|
Device consumption for the procedure
Time Frame: 1 day (Immidiately after procedure)
|
Device consumption is defined as the number and type of catheter, guidewire, balloon and stent used procedurally.
|
1 day (Immidiately after procedure)
|
Guiding catheter size used
Time Frame: 1 day (Immidiately after procedure)
|
1 day (Immidiately after procedure)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lianglong Chen, PhD, MD, Union Hospital, Fujian Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- the DK CULOTTE-I study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Heart Disease
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Shenyang Northern HospitalNot yet recruitingCoronary Heart Disease (CHD)China
-
Johns Hopkins UniversityCanon Medical Systems, USARecruiting
-
MedImmune LLCCompletedStable Coronary Heart DiseaseUnited States
-
Medical University of LodzBaxter Healthcare CorporationUnknownCHD - Coronary Heart DiseasePoland
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland
-
Hamad Medical CorporationMayo ClinicCompleted
-
Henan Institute of Cardiovascular EpidemiologyNot yet recruitingStable Coronary Heart Disease
Clinical Trials on Resolute stents
-
Seoul National University HospitalMedtronicUnknownCoronary Artery DiseaseKorea, Republic of
-
Tomsk National Research Medical Center of the Russian...CompletedCoronary Heart Disease | Stable Angina Pectoris | Silent Myocardial IschemiaRussian Federation
-
Ajou University School of MedicineMedtronicUnknownAcute Myocardial InfarctionKorea, Republic of
-
Changhai HospitalUnknownAortic Aneurysm, Abdominal | Aortic Aneurysm | Aortic Aneurysm, Thoracic | Aortic Aneurysm, ThoracoabdominalChina
-
Yonsei UniversityMedtronicCompletedCoronary Artery DiseaseKorea, Republic of
-
UMC UtrechtUnknownAcute Coronary Syndrome | Stable Angina PectorisNetherlands, Luxembourg
-
Medtronic Bakken Research CenterCompletedCoronary Artery DiseaseSpain
-
Washington University School of MedicineMassachusetts General Hospital; Ontario Clinical Oncology Group (OCOG); St. Luke...RecruitingDeep Vein Thrombosis | Post Thrombotic Syndrome | Venous Insufficiency | Venous Leg Ulcer | Venous Stasis | Venous RefluxUnited States
-
Shanghai Jiao Tong University School of MedicineCompletedCoronary Artery Disease | DiabetesChina
-
University of PadovaActive, not recruitingCoronary Artery DiseaseItaly, Portugal